The CHMP recommended marketing authorization for Eltrombopag Viatris, a generic medicine for primary immune thrombocytopenia, thrombocytopenia associated with chronic hepatitis C virus, and severe aplastic anemia. It is bioequivalent to the reference product Revolade and stimulates platelet production by interacting with the thrombopoietin receptor. It is indicated for adults and children with primary ITP, and adults with chronic HCV infection. Treatment should be supervised by experienced doctors due to serious adverse reactions like hepatotoxicity and thromboembolic events. Common side effects include headache, nausea, and fatigue. Detailed recommendations will be included in the product characteristics after marketing authorization is granted.
Source link
Generic Medicine OKd by Europe for Thrombocytopenia With HCV
